IP Library Granted Patent US 8,263,647
Granted Patent B2
US 8,263,647 · App. 12/082,342 · Granted Sep 11, 2012

Treatment of sleep disturbances

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,647
App. No.
12/082,342
Granted
Sep 11, 2012
Kind
B2
Abstract

The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.

Claims (18)

1. A solid dosage form comprising ibuprofen and diphenhydramine in amounts effective to treat a pain-associated sleep disturbance, wherein the solid dosage form has a bilayer configuration having a first layer and a second layer, wherein the first layer comprises all of the ibuprofen in an amount from 50 mg to 800 mg and the second layer comprises the diphenhydramine or a salt thereof in an amount from 12.5 mg to 50 mg.

2. The composition of claim 1 , wherein the ibuprofen is present in an amount of 200 mg.

3. The composition of claim 1 , wherein the diphenhydramine is present as diphenhydramine HCl or diphenhydramine citrate.

4. The composition of claim 3 , wherein the diphenhydramine is present as diphenhydramine HCl or diphenhydramine citrate.

5. The composition of claim 4 , wherein the diphenhydramine HCl is present in an amount of 25 mg.

6. The composition of claim 4 , wherein the diphenhydramine citrate is present in an amount from 19 mg to 38 mg.

7. The composition of claim 6 wherein the diphenhydramine citrate is present in an amount of 38 mg.

8. The composition of claim 7 , wherein the sleep disturbance affects sleep duration.

9. A composition to treat a pain-associated sleep disturbance comprising a liquid composition formulated inside a soft gelatin capsule, wherein said liquid composition consisting of about 200 to about 400 mg of ibuprofen and between about 10 to about 50 mg of diphenhydramine, and a solubilizing agent consisting of polyethylene glycol to prevent negative interactions between the ibuprofen and the diphenhydramine.

10. The composition of claim 9 , wherein the ibuprofen is present in an amount of 200 mg.

11. The composition of claim 10 , wherein the diphenhydramine is present as diphenhydramine HCl or diphenhydramine citrate.

12. The composition of claim 11 , wherein the diphenhydramine is present as diphenhydramine HCl or diphenhydramine citrate.

13. The composition of claim 12 , wherein the diphenhydramine HCl is present in an amount from 12.5 mg to 50 mg.

14. The composition of claim 13 , wherein the diphenhydramine HCl is present in an amount of 25 mg.

15. The composition of, claim 11 wherein the diphenhydramine citrate is present in amount from 19 mg to 38 mg.

16. The composition of claim 15 , wherein the diphenhydramine citrate is present in an amount of 38 mg.

17. The composition of claim 9 , wherein the sleep disturbance affects sleep duration.

18. A solid dosage form comprising ibuprofen and diphenhydramine in amounts effective to treat a pain-associated sleep disturbance, wherein the solid dosage form has a configuration having a first layer and a second layer, wherein the first layer comprises all of the ibuprofen and the second layer comprises the diphenhydramine or a salt thereof, thereby minimizing the negative interaction between the diphenhydramine and the ibuprofen, wherein the solid dosage form further comprises at least one of calcium stearate, croscarmellose sodium, glyceryl behenate, lactose, microcrystalline cellulose, silicon dioxide colloidal, sodium lauryl sulfate, sodium starch glycolate, corn starch, preglatinized starch, starch or stearic acid.

Assignments (5)
CHANGE OF NAME Recorded Mar 1, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066713/0558 →
CHANGE OF NAME Recorded Feb 28, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066701/0387 →
MERGER AND CHANGE OF NAME Recorded Apr 6, 2022
From: PF CONSUMER HEALTHCARE 1 LLC; GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
Reel/Frame 059620/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: WYETH LLC
To: PF CONSUMER HEALTHCARE 1 LLC
Reel/Frame 050727/0184 →
ARTICLES OF ORGANIZATION-CONVERSION Recorded May 26, 2016
From: WYETH
To: WYETH LLC
Reel/Frame 038822/0194 →